Table 4. Patients who achieved durable disease stability (≥24 weeks): Demographics, PFS and OS.
| Patient Identifier | Primary Disease | Age – years | Prior therapies – No. | BRCA Status | Veliparib Dose – mg/day | Continued veliparib maintenance? - yes/no | PFS – mo. | OS – mo. |
|---|---|---|---|---|---|---|---|---|
| 2 | PERITONEAL MESOTHELIOMA | 65 | 2 | N/A | 80 | NO | 23.26 | 24.27 |
| 4 | URACHAL | 55 | 1 | N/A | 160 | NO | 5.42 | 22.66 |
| 7 | OVARIAN | 55 | 7 | NEGATIVE | 160 | YES | 6.76 | 10.58 |
| 8 | OVARIAN | 75 | 6 | UNKNOWN | 160 | NO | 9.72 | 17.54 |
| 9 | OVARIAN | 50 | 1 | UNKNOWN | 160 | NO | 12.78 | 18.99 |
| 13 | SMALL BOWEL | 69 | 2 | N/A | 240 | NO | 5.51 | 15.08 |
| 15 | FALLOPIAN | 63 | 4 | POSITIVE | 240 | YES | 7.91 | 8.64 |